钆贝葡胺增强肝胆期病灶低信号作为LI-RADS v2018额外主要特征用于HCC分类的价值
本研究纳入235例250个高危肝结节,评估钆贝葡胺增强MRI肝胆期病灶低信号作为LI-RADS v2018额外主要特征诊断HCC的价值。结果显示,将肝胆期低信号作为额外主要特征(LI-RADS-m1)可显著提高LR-5分类的敏感度(78.1%→82.7%,p=0.004),特异度不变(96.3%);在10-19 mm结节中,两种改良定义均较原始标准显著提高敏感度(79.5% vs 64.0%,p=0.031)。
要点
- 肝胆期低信号作为额外主要特征可提高LR-5分类敏感度,特异度不变。
- 肝胆期低信号可替代「增强包膜」作为额外主要特征,诊断效能相似。
- 在10-19 mm小结节中,改良标准较原始LI-RADS v2018显著提高敏感度。
诊断标准与关键数值
- 原始LI-RADS v2018标准LR-5分类敏感度78.1%、特异度96.3%。
- LI-RADS-m1(肝胆期低信号作为额外主要特征)LR-5分类敏感度82.7%(p=0.004 vs 原始)、特异度96.3%(p=1.00)。
- LI-RADS-m2(肝胆期低信号替代增强包膜作为额外主要特征)LR-5分类敏感度82.7%、特异度96.3%。
- 10-19 mm结节(39个)中,LI-RADS-m1和m2较原始标准敏感度79.5% vs 64.0%(p=0.031),特异度96.2% vs 96.2%(p=1.00)。
临床应用与阅片要点
- 在钆贝葡胺增强MRI肝胆期,可将病灶低信号视为额外主要特征以提高LR-5分类敏感度。
- 当增强包膜不明确时,肝胆期低信号可作为替代特征用于LR-5分类,且不损害特异度。
- 对10-19 mm小结节,采用改良标准可提高HCC诊断敏感度。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the value of lesion hypointensity in the hepatobiliary phase (HBP) on gadobenate dimeglumine-enhanced MRI as an additional major imaging feature for diagnosis of hepatocellular carcinoma (HCC) using LI-RADS v2018 criteria.
METHODS: Between March 2016 and August 2018, 235 patients with 250 hepatic nodules at high risk of HCC underwent gadobenate dimeglumine-enhanced MRI. Two radiologists independently evaluated the imaging features and classified the nodules based on LI-RADS v2018 criteria, and their consensus data were used to calculate the diagnostic performance of LI-RADS categories. Two modified LI-RADS definitions were as follows: (1) LI-RADS-m1: HBP hypointensity as an additional major feature; (2) LI-RADS-m2: HBP hypointensity as an alternative to "enhancing capsule" as an additional major feature. The diagnostic performance of LR-5 categories was compared using McNemar's test.
RESULTS: The sensitivity and specificity for LR-5 classification using original LI-RADS v2018 criteria were 78.1% and 96.3%, respectively. Significantly improved sensitivity (82.7%; p = 0.004) with unchanged specificity (96.3%; p = 1.00) was seen for LR-5 classification using LI-RADS-m1. Similar sensitivity and specificity (82.7% and 96.3%, respectively) were also seen using LI-RADS-m2. Significantly improved sensitivity (79.5% vs. 64.0%; p = 0.031) with unchanged specificity (96.2% vs. 96.2%, p = 1.00) was seen using both LI-RADS-m1 and LI-RADS-m2 compared to the original LI-RADS v2018 for 39 HCC nodules measuring 10-19 mm.
CONCLUSIONS: Lesion hypointensity on gadobenate dimeglumine-enhanced HBP MRI may improve sensitivity for LR-5 classification beyond that achievable using conventional LI-RADS v2018 criteria. Lesion hypointensity may prove a suitable alternative imaging feature to enhancing capsule for accurate LR-5 classification.
KEY POINTS: • Including lesion hypointensity in the HBP as an additional major feature improved sensitivity for LR-5 classification on gadobenate dimeglumine-enhanced MRI. • Lesion hypointensity in the HBP can replace "enhancing capsule" as an additional major feature for LR-5 classification without impairing specificity.
引用
- Zhang Y, Tang W, Xie S, et al. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria. Eur Radiol. 2021. PMID: 33782766. doi:10.1007/s00330-021-07807-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。